These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 11354395)

  • 1. Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance symposium. Biannual Foothills Meeting on Osteoporosis, Calgary, Alberta, Canada, September 9-10, 2000.
    Drake WM; Kendler DL; Brown JP
    Clin Ther; 2001 Apr; 23(4):620-6. PubMed ID: 11354395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risedronate: a new oral bisphosphonate.
    Umland EM; Boyce EG
    Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Paget's disease and its therapeutic management].
    Orcel P; Rousière M
    Presse Med; 2005 Apr; 34(8):612-6. PubMed ID: 15962504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group.
    Miller PD; Brown JP; Siris ES; Hoseyni MS; Axelrod DW; Bekker PJ
    Am J Med; 1999 May; 106(5):513-20. PubMed ID: 10335722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates for Paget's disease of bone in adults.
    Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates for osteoporosis.
    Drug Ther Bull; 2001 Sep; 39(9):68-72. PubMed ID: 11586803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
    Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
    Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone.
    Roux C; Gennari C; Farrerons J; Devogelaer JP; Mulder H; Kruse HP; Picot C; Titeux L; Reginster JY; Dougados M
    Arthritis Rheum; 1995 Jun; 38(6):851-8. PubMed ID: 7779130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of drugs for Paget's disease of bone.
    Reginster JY; Lecart MP
    Bone; 1995 Nov; 17(5 Suppl):485S-488S. PubMed ID: 8573423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
    Reid IR; Miller P; Lyles K; Fraser W; Brown JP; Saidi Y; Mesenbrink P; Su G; Pak J; Zelenakas K; Luchi M; Richardson P; Hosking D
    N Engl J Med; 2005 Sep; 353(9):898-908. PubMed ID: 16135834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical management of Paget's disease of bone: indications for treatment and review of current therapies.
    Siris ES; Lyles KW; Singer FR; Meunier PJ
    J Bone Miner Res; 2006 Dec; 21 Suppl 2():P94-8. PubMed ID: 17229018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modern therapy for Paget's disease of bone: focus on bisphosphonates.
    Devogelaer JP
    Treat Endocrinol; 2002; 1(4):241-57. PubMed ID: 15799218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone.
    Siris E; Weinstein RS; Altman R; Conte JM; Favus M; Lombardi A; Lyles K; McIlwain H; Murphy WA; Reda C; Rude R; Seton M; Tiegs R; Thompson D; Tucci JR; Yates AJ; Zimering M
    J Clin Endocrinol Metab; 1996 Mar; 81(3):961-7. PubMed ID: 8772558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paget's disease and bisphosphonates.
    Rendina D; De Filippo G; Mossetti G
    N Engl J Med; 2005 Dec; 353(24):2616-8; author reply 2616-8. PubMed ID: 16365936
    [No Abstract]   [Full Text] [Related]  

  • 15. Two cases of monostotic Paget's disease: effects of bisphosphonate.
    Hoshiro M; Harada T; Iwai H; Miyatake T; Nishimura A; Ohno Y; Aoki N
    Endocr J; 2003 Aug; 50(4):385-92. PubMed ID: 14599111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Paget's disease of bone: a survey of clinical practice in Australia.
    Walsh JP; Attewell R; Stuckey BG; Hooper MJ; Wark JD; Fletcher S; Ferrari V; Eisman JA
    Bone; 2008 Jun; 42(6):1219-25. PubMed ID: 18353737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonate therapy.
    Licata AA
    Am J Med Sci; 1997 Jan; 313(1):17-22. PubMed ID: 9001162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
    Rendina D; Mossetti G; Viceconti R; Sorrentino M; Nunziata V
    Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
    Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N
    Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.